pembrolizumab,lenvatinib
eisai,merck
['hcc', 'leap-002', 'pembro', 'lenva']
negative results of leap-002 presented at #esmo22 by dr finn with lenva plus pembro in hcc unresectable or metastatic hcc.
lenvatinib monotherapy achieved os of 19 months. 
Medical Oncologist, GI tumors and NET, @INCMNSZ